Cart
sales@molnova.com
6-Hydroxyluteolin
CAS No. 18003-33-3
6-Hydroxyluteolin( ——— )
Catalog No. M38264 CAS No. 18003-33-3
6-Hydroxyluteolin (Compound 17) is a flavonoid compound. 6-Hydroxyluteolin has an inhibitory effect on aldose reductase (AR) .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 369 | In Stock |
|
| 10MG | 588 | In Stock |
|
| 25MG | 1169 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name6-Hydroxyluteolin
-
NoteResearch use only, not for human use.
-
Brief Description6-Hydroxyluteolin (Compound 17) is a flavonoid compound. 6-Hydroxyluteolin has an inhibitory effect on aldose reductase (AR) .
-
Description6-Hydroxyluteolin (Compound 17) is a flavonoid compound. 6-Hydroxyluteolin has an inhibitory effect on aldose reductase (AR) .
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number18003-33-3
-
Formula Weight302.24
-
Molecular FormulaC15H10O7
-
Purity>98% (HPLC)
-
SolubilityMethanol : 4 mg/mL (13.23 mM; ultraphonic)
-
SMILESO=C1C=C(OC2=CC(O)=C(O)C(O)=C12)C=3C=CC(O)=C(O)C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mercader AG, et al. QSAR prediction of inhibition of aldose reductase for flavonoids. Bioorg Med Chem. 2008. 16(15):7470-6.?
molnova catalog
related products
-
BODIPY 493/503
BODIPY 493/503 is a lipophilic fluorescent probe with Ex/Em of 493/503 nm. BODIPY 493/503 localizes to polar lipids and can be used to label cellular neutral lipid contents and for live and fixed cell applications.
-
AUDA
AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes respectively).
-
Toddaculin
Toddaculine may be beneficial for the prevention and treatment of osteoporosis, it can not only inhibit the differentiation of osteoclasts via activation of the NF-κB, ERK 1/2, and p38 MAPK signaling pathways.
